The clinical development plan for Enara's novel therapies is a two-step process. First, establish monotherapy efficacy in late-line patients to get a clear signal. The ultimate goal, however, is to quickly move into earlier lines of therapy in combination with standard of care, where the market opportunity and patient benefit are greatest.

Ophthalmology has become a "safe haven" for gene therapy because it mitigates the field's two main challenges: safety and manufacturing. Localized delivery to the immune-privileged eye improves the safety profile, while the thousand-fold lower required doses simplify manufacturing and dramatically improve the cost of goods.

Beyond its current late-stage trial, iOnctura's key ambition is to use its well-tolerated oral drug in the adjuvant setting. The goal is to prevent metastasis in the 50% of patients who relapse after primary eye treatment, fundamentally changing their prognosis rather than just managing late-stage disease.

Iolyx CEO Elizabeth Jeffords insists on commercial input even in preclinical stages. This meant killing an ointment formulation—which patients find 'greasy' and 'disgusting'—in favor of developing a more patient-friendly eyedrop. This avoids creating a product that is clinically sound but has poor real-world adoption.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

Newscom's strategy is to "intercept" cancer before tumors can form, a significant shift from traditional treatment. By training the immune system to eliminate precancerous cells as they emerge in high-risk groups like Lynch syndrome carriers, they move from reactive treatment to proactive prevention at a cellular level.

The current boom in immunology and autoimmune (I&I) therapeutics is not a separate phenomenon but a direct consequence of capital and knowledge from immuno-oncology. Many of the same biological pathways are being targeted, simply modulated down (for autoimmune) instead of up (for cancer), allowing for rapid therapeutic advancement and platform reuse.

The field of ophthalmology is particularly well-suited for a hub-and-spoke model because it utilizes a wide range of treatment modalities (small molecules, biologics, devices, gene therapy). This allows a central hub to leverage shared expertise in areas like ocular delivery and regulatory pathways across multiple, diverse spokes.

Instead of creating another 'more durable' version of existing drugs, Iolyx Therapeutics was founded to address the immunological roots of many eye diseases. CEO Elizabeth Jeffords notes that while conditions like Sjogren's are known to be autoimmune, treatments often fail to target the underlying immune process locally within the eye.